Send comments and news tips to [email protected]. Cite this: Edited by Shrabasti Bhattacharya. Difficult-to-Treat IBD Patients Prefer Dual Biologic Therapy - Medscape - March 12, 2025.

TAKEAWAY: Among 11,992 adult patients newly initiating biologic therapy (median age, 47 years; 52.7% women), 1293 (10.8%) underwent a biologic switch during a minimum follow-up of 90 days.

Before and During the Induction Phase of Treatment The single most important factor for optimization of therapy for IBD at the initiation of treatment is ascertainment of active IBD inflammation.

OAKVILLE, ON, May 19, 2015 /CNW/ - ENTYVIO™ (vedolizumab), a new biologic treatment to treat ulcerative colitis (UC), one of the two most common types of inflammatory bowel disease, is now ...

Respondr TNF is the first test to predict an inflammatory bowel disease (IBD) patient's likelihood to respond to infliximab, adalimumab and their biosimilars prior to therapy administration.